Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Joinn Laboratories (China) Co FCF Yield %?
Joinn Laboratories (China) CoSHSE:603127 +3.72%78 FCF Yield % is 0.14 as of Aug. 01, 2026, which is 87% below its 10-year median of 1.07. GuruFocus rates SHSE:603127 with a GF Score™ of 78/100 and a GF Value™ of ¥17.43 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Joinn Laboratories (China) Co ranks better than 54.46% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Joinn Laboratories (China) Co's FCF Yield % or its related term are showing as below:
SHSE:603127'
s FCF Yield % Range Over the Past 10 Years
Min: -0.01 Med: 1.07 Max: 5.59
Current: 0.14
During the past 13 years, the highest FCF Yield % of Joinn Laboratories (China) Co was 5.59%. The lowest was -0.01%. And the median was 1.07%.
SHSE:603127's FCF Yield % is ranked better than 54.46% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.15
vs SHSE:603127: 0.14
Joinn Laboratories (China) Co FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Joinn Laboratories (China) Co FCF Yield % Related Terms
Joinn Laboratories (China) Co FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603127 vs TMO, DHR, IDXX: FCF Yield % Comparison
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co (SHSE:603127) has a FCF Yield % of 0.14 as of Aug. 01, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Joinn Laboratories (China) Co and its competitors. This is 87% below median its historical median of 1.07. According to the industry distribution chart, Joinn Laboratories (China) Co ranks #97 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 45.5%.
Is Joinn Laboratories (China) Co's FCF Yield % too high?
Joinn Laboratories (China) Co's current FCF Yield % of 0.14 is 87% below median its 10-year median of 1.07. Based on the distribution chart, Joinn Laboratories (China) Co ranks #97 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Joinn Laboratories (China) Co has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Joinn Laboratories (China) Co's FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Joinn Laboratories (China) Co ranks #97 out of 213 companies for FCF Yield %. This puts Joinn Laboratories (China) Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Joinn Laboratories (China) Co and its competitors. Joinn Laboratories (China) Co's current FCF Yield % is 0.14, which is 87% below median its own 10-year median of 1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joinn Laboratories (China) Co stock overvalued right now?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co (SHSE:603127) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.43, compared to a current price of ¥41.54 — trading 138.3% above its estimated fair value. The current FCF Yield % is 0.14, which is 87% below median its 10-year median of 1.07. Joinn Laboratories (China) Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Joinn Laboratories (China) Co (SHSE:603127), the current FCF Yield % is 0.14 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued.
The current stock price of ¥41.54 is trading 138.3% above its estimated GF Value™ of ¥17.43.
GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.
Key valuation signals for SHSE:603127:
FCF Yield %: 0.14 (87% below median its 10-year median of 1.07)
GF Value™: ¥17.43 vs. price of ¥41.54 (138.3% above fair value)
No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
78GF Score
Get the complete analysis for SHSE:603127
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603127 has been successfully added to your 
